30 results on '"Campos-Martorell, Ariadna"'
Search Results
2. Clinical and genetic characteristics of a large international cohort of individuals with rare NR5A1/SF-1 variants of sex development
- Author
-
Abali, Saygin, Abali, Zehra Yavas, Akin, Leyla, Almaraz, Maricruz, Audí, Laura, Aydin, Murat, Balsamo, Antonio, Baronio, Federico, Bryce, Jillian, Busiah, Kanetee, Caimari, Maria, Camats-Tarruella, Núria, Campos-Martorell, Ariadna, Castaño, Luis, Casteràs, Anna, Çetinkaya, Semra, Chan, Yee-Ming, Claahsen-van der Grinten, Hedi L., Costa, Ines, Darendeliler, Fatma Feyza, Davies, Justin H., Esteva, Isabel, Fabbri-Scallet, Helena, Finlayson, Courtney A., Garcia, Emilio, Garcia Cuartero, Beatriz, German, Alina, Globa, Evgenia, Guerra-Junior, Gil, Guerrero, Julio, Guran, Tulay, Hannema, Sabine E., Hiort, Olaf, Hirsch, Josephine, Hughes, Leuan, Janner, Marco, Kolesinska, Zofia, Lachlan, Katherine, Lauber-Biason, Anna, Malikova, Jana Krenek, l'Allemand, Dagmar, Lenhnerr-Taube, Nina, Lucas-Herald, Angela, Mammadova, Jamala, MсElreavey, Kenneth, Mericq, Veronica, Mönig, Isabel, Moreno, Francisca, Mührer, Julia, Niedziela, Marek, Nordenstrom, Anna, Orman, Burçe, Poyrazoglu, Sukran, Rial, Jose M., Rutter, Meilan M., Rodríguez, Amaia, Schafer-Kalkhoff, Tara, Sauter, Kay-Sara, Seneviratne, Sumudu Nimali, Sredkova-Ruskova, Maria, Tadokoro-Cuccaro, Rieko, Thankamony, Ajay, Tomé, Mónica, Vela, Amaia, Wasniewska, Malgorzata, Zangen, David, Zelinska, Nataliya, Kouri, Chrysanthi, Sommer, Grit, Martinez de Lapiscina, Idoia, Elzenaty, Rawda Naamneh, Tack, Lloyd J.W., Cools, Martine, Ahmed, S. Faisal, and Flück, Christa E.
- Published
- 2024
- Full Text
- View/download PDF
3. Patient with adrenal insufficiency due to a de novo mutation in the NR0B1 gene
- Author
-
Bravo Nieto Daniel, García Fernández Alba S., Díaz Troyano Noelia, Arnaiz Marina Giralt, Arias García Andrea, Fernández Álvarez Paula, Campos Martorell Ariadna, Ferrer Costa Roser, and Clemente León María
- Subjects
adrenal insufficiency ,congenital adrenal hypoplasia ,nr0b1 ,Medical technology ,R855-855.5 - Abstract
Congenital X-linked adrenal hypoplasia is a rare disease with a known genetic basis characterized by adrenal insufficiency, hypogonadotropic hypogonadism, and a wide variety of clinical manifestations.
- Published
- 2023
- Full Text
- View/download PDF
4. Paciente con insuficiencia suprarrenal por mutación de novo en el gen NR0B1
- Author
-
Bravo Nieto Daniel, García Fernández Alba S., Diaz Troyano Noelia, Giralt Arnaiz Marina, Arias García Andrea, Fernández Álvarez Paula, Campos Martorell Ariadna, Ferrer Costa Roser, and Clemente León María
- Subjects
hipoplasia adrenal congénita ,insuficiencia suprarrenal ,nr0b1 ,Medical technology ,R855-855.5 - Abstract
La hipoplasia suprarrenal congénita ligada al cromosoma X es una enfermedad rara con base genética conocida, que se presenta con insuficiencia suprarrenal e hipogonadismo hipogonadotrófico y expresión clínica variable.
- Published
- 2023
- Full Text
- View/download PDF
5. Thyroid function in < 32 weeks gestation preterm infants
- Author
-
Montaner-Ramón, Alicia, Hernández-Pérez, Susana, Campos-Martorell, Ariadna, Ballesta-Anguiano, Marta, Clemente-León, María, and Castillo-Salinas, Félix
- Published
- 2022
- Full Text
- View/download PDF
6. Función tiroidea en el recién nacido prematuro con edad gestacional igual o menor a 32 semanas
- Author
-
Montaner-Ramón, Alicia, Hernández-Pérez, Susana, Campos-Martorell, Ariadna, Ballesta-Anguiano, Marta, Clemente-León, María, and Castillo- Salinas, Félix
- Published
- 2022
- Full Text
- View/download PDF
7. Criterios ecográficos (EU-TIRADS) para identificar el riesgo de malignidad de los nódulos tiroideos en adolescentes. Correlación con los hallazgos cito-histológicos
- Author
-
Yeste Fernández, Diego, Vega Amenabar, Elizabeth, Coma Muñoz, Ana, Arciniegas Vallejo, Larry, Clemente León, María, Planes-Conangla, Marina, Iglesias Felip, Carmela, Sábado Álvarez, Constantino, Guillén Burrieza, Gabriela, and Campos-Martorell, Ariadna
- Published
- 2021
- Full Text
- View/download PDF
8. Ultrasound criteria (EU-TIRADS) to identify thyroid nodule malignancy risk in adolescents. Correlation with cyto-histological findings
- Author
-
Yeste Fernández, Diego, Vega Amenabar, Elizabeth, Coma Muñoz, Ana, Arciniegas Vallejo, Larry, Clemente León, María, Planes-Conangla, Marina, Iglesias Felip, Carmela, Sábado Álvarez, Constantino, Guillén Burrieza, Gabriela, and Campos-Martorell, Ariadna
- Published
- 2021
- Full Text
- View/download PDF
9. Seventy eight children born small for gestational age without catch-up growth treated with growth hormone from the prepubertal stage until adult height age. An evaluation of puberty and changes in the metabolic profile
- Author
-
Campos-Martorell, Ariadna, Fernández-Cancio, Mónica, Clemente León, María, Mogas Viñals, Eduard, Fàbregas Martori, Anna, Carrascosa Lezcano, Antonio, and Yeste Fernández, Diego
- Published
- 2021
- Full Text
- View/download PDF
10. Genetic and Functional Studies of Patients with Thyroid Dyshormonogenesis and Defects in the TSH Receptor (TSHR).
- Author
-
Yeste, Diego, Baz-Redón, Noelia, Antolín, María, Garcia-Arumí, Elena, Mogas, Eduard, Campos-Martorell, Ariadna, González-Llorens, Núria, Aguilar-Riera, Cristina, Soler-Colomer, Laura, Clemente, María, Fernández-Cancio, Mónica, and Camats-Tarruella, Núria
- Subjects
CONGENITAL hypothyroidism ,CHILD patients ,NEWBORN screening ,GENETIC variation ,THYROID gland - Abstract
Genetic defects in the TSH receptor (TSHR) can cause poor thyroid differentiation (thyroid dysgenesis) and/or thyroid malfunction (thyroid dyshormonogenesis). The phenotype spectrum is wide: from severe congenital hypothyroidism to mild hyperthyrotropinemia. Over 250 TSHR variants have been published, many uncharacterized in vitro. We aimed to genetically characterize patients with thyroid dyshormonogenesis with TSHR defects and to study in vitro the effect of the genetic variants to establish the genotype–phenotype relationship. Pediatric patients with thyroid dyshormonogenesis (160 patients, Catalan CH neonatal screening program, confirmation TSH range: 18.4–100 mIU/L), were analyzed by a high-throughput gene panel. In vitro studies measuring the TSH-dependent cAMP–response–element activation were performed. Five patients with mild or severe thyroid dyshormonogenesis presented six TSHR variants, two unpublished. Each variant showed a different in vitro functional profile that was totally or partially deleterious. Depending on the genotype, some of the variants showed partial deficiency in both genotypes, whereas others presented a different effect. In conclusion, the percentage of patients with thyroid dyshormonogenesis and candidate variants in TSHR is 3.13%. Our in vitro studies contributed to the confirmation of the pathogenicity of the variants and highlighted the importance of studying the effect of the patient's genotype for a correct diagnostic confirmation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Clinical and genetic characteristics of a large international cohort of individuals with rare NR5A1/SF-1 variants of sex development
- Author
-
Kouri, Chrysanthi, primary, Sommer, Grit, additional, Martinez de Lapiscina, Idoia, additional, Elzenaty, Rawda Naamneh, additional, Tack, Lloyd J.W., additional, Cools, Martine, additional, Ahmed, S. Faisal, additional, Flück, Christa E., additional, Abali, Saygin, additional, Abali, Zehra Yavas, additional, Akin, Leyla, additional, Almaraz, Maricruz, additional, Audí, Laura, additional, Aydin, Murat, additional, Balsamo, Antonio, additional, Baronio, Federico, additional, Bryce, Jillian, additional, Busiah, Kanetee, additional, Caimari, Maria, additional, Camats-Tarruella, Núria, additional, Campos-Martorell, Ariadna, additional, Castaño, Luis, additional, Casteràs, Anna, additional, Çetinkaya, Semra, additional, Chan, Yee-Ming, additional, Claahsen-van der Grinten, Hedi L., additional, Costa, Ines, additional, Darendeliler, Fatma Feyza, additional, Davies, Justin H., additional, Esteva, Isabel, additional, Fabbri-Scallet, Helena, additional, Finlayson, Courtney A., additional, Garcia, Emilio, additional, Garcia Cuartero, Beatriz, additional, German, Alina, additional, Globa, Evgenia, additional, Guerra-Junior, Gil, additional, Guerrero, Julio, additional, Guran, Tulay, additional, Hannema, Sabine E., additional, Hiort, Olaf, additional, Hirsch, Josephine, additional, Hughes, Leuan, additional, Janner, Marco, additional, Kolesinska, Zofia, additional, Lachlan, Katherine, additional, Lauber-Biason, Anna, additional, Malikova, Jana Krenek, additional, l'Allemand, Dagmar, additional, Lenhnerr-Taube, Nina, additional, Lucas-Herald, Angela, additional, Mammadova, Jamala, additional, MсElreavey, Kenneth, additional, Mericq, Veronica, additional, Mönig, Isabel, additional, Moreno, Francisca, additional, Mührer, Julia, additional, Niedziela, Marek, additional, Nordenstrom, Anna, additional, Orman, Burçe, additional, Poyrazoglu, Sukran, additional, Rial, Jose M., additional, Rutter, Meilan M., additional, Rodríguez, Amaia, additional, Schafer-Kalkhoff, Tara, additional, Sauter, Kay-Sara, additional, Seneviratne, Sumudu Nimali, additional, Sredkova-Ruskova, Maria, additional, Tadokoro-Cuccaro, Rieko, additional, Thankamony, Ajay, additional, Tomé, Mónica, additional, Vela, Amaia, additional, Wasniewska, Malgorzata, additional, Zangen, David, additional, and Zelinska, Nataliya, additional
- Published
- 2024
- Full Text
- View/download PDF
12. Clinical and molecular study of patients with thyroid dyshormogenesis and variants in the thyroglobulin gene.
- Author
-
Fernández-Cancio, Mónica, Antolín, María, Clemente, María, Campos-Martorell, Ariadna, Mogas, Eduard, Baz-Redón, Noelia, Leno-Colorado, Jordi, Comas-Armangué, Gemma, García-Arumí, Elena, Soler-Colomer, Laura, González-Llorens, Núria, Camats-Tarruella, Núria, and Yeste, Diego
- Subjects
GENETIC variation ,CONGENITAL hypothyroidism ,HORMONE synthesis ,THYROID gland ,NUCLEOTIDE sequencing - Abstract
Introduction: Defects in any thyroid hormone synthesis steps cause thyroid dyshormonogenesis (THD). THD due to thyroglobulin (TG) gene variants is a cause of congenital hypothyroidism (CH) with a wide clinical spectrum, ranging from mild to severe permanent hypothyroidism. We present high-throughput sequencing results of patients with TG variants. Methods: A CH high-throughput sequencing-panel of the main genes involved in the regulation of thyroid hormonogenesis was performed to identify those TG variants that may be related to patient THD phenotype. Results: We identified 21 TG gene variants in 19 patients (11.8%) which could explain their phenotype. Ten of those (47.6%) were not previously described. CH was biochemically severe in these 19 patients. Eight of them were reevaluated after one month of discontinuing LT4 treatment and all had severe permanent hypothyroidism. We also identified another 16 patients who presented heterozygous TG variants, of whom, at reevaluation, five had mild permanent and only one had severe permanent hypothyroidisms. Discussions: In this study, 10 novel and 11 previously reported variants in the TG gene have been identified that could explain the phenotype of 19 patients from non-consanguineous families from a large THD cohort. Although not all these TG gene variants can explain all the patients' THD phenotypes, some of them had severe or mild permanent hypothyroidism at reevaluation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Clinical practice guidelines for transsexual, transgender and gender diverse minors
- Author
-
Moral-Martos, Amadora, Guerrero-Fernández, Julio, Gómez-Balaguer, Marcelino, Rica Echevarría, Itxaso, Campos-Martorell, Ariadna, Chueca-Guindulain, María Jesús, García García, Emilio, Hoyos-Gurrea, Raúl, López de Lara, Diego, López-Siguero, Juan Pedro, Martos Tello, José María, Mora Palma, Cristina, Riaño Galán, Isolina, and Yeste Fernández, Diego
- Published
- 2022
- Full Text
- View/download PDF
14. Guía clínica de atención a menores transexuales, transgéneros y de género diverso
- Author
-
Moral-Martos, Amadora, Guerrero-Fernández, Julio, Gómez Balaguer, Marcelino, Rica Echevarría, Itxaso, Campos-Martorell, Ariadna, Chueca-Guindulain, María Jesús, García García, Emilio, Hoyos-Gurrea, Raúl, López de Lara, Diego, López-Siguero, Juan Pedro, Martos Tello, José María, Mora Palma, Cristina, Riaño Galán, Isolina, and Yeste Fernández, Diego
- Published
- 2022
- Full Text
- View/download PDF
15. Hemangiomatosis hepática de inicio neonatal.
- Author
-
Román Denia, Pilar, López Liñán, M. ª. José, Guevara Caviedes, Laura Nathalia, Quilis Esquerra, Josep, Sánchez Garre, M. ª. Consuelo, Campos-Martorell, Ariadna, and López Fernández, Sergio
- Subjects
LIVER tumors ,THYROXINE ,HEMANGIOMAS ,TUMORS in children ,BLOOD testing ,MAGNETIC resonance imaging ,HEPATOMEGALY ,ANGIOMATOSIS ,PROPANOLS ,EARLY diagnosis ,HYPOTHYROIDISM ,CHOLESTASIS ,CHILDREN - Abstract
Copyright of Revista Pediatría de Atención Primaria is the property of LUA Ediciones 3.0 S.L. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
16. Contribution of Dynamic and Genetic Tests for Short Stature Diagnosing: A Case Report
- Author
-
Biagetti, Betina, primary, Valenzuela, Irene, additional, Campos-Martorell, Ariadna, additional, Campos, Berta, additional, Hernandez, Sara, additional, Giralt, Marina, additional, Díaz-Troyano, Noelia, additional, Iniesta-Serrano, Emilio, additional, Yeste, Diego, additional, and Simó, Rafael, additional
- Published
- 2023
- Full Text
- View/download PDF
17. Pituitary Macroadenomas in Childhood and Adolescence: A Clinical Analysis of 7 Patients
- Author
-
aguilar-riera, cristina, primary, Clemente, María, additional, Gonzalez-Llorens, Núria, additional, Mogas, Eduard, additional, Campos-Martorell, Ariadna, additional, Fàbregas, Anna, additional, Biagetti, Betina, additional, Vázquez, Elida, additional, and Yeste, Diego, additional
- Published
- 2023
- Full Text
- View/download PDF
18. Thyroid Function in 509 Premature Newborns Below 31 Weeks of Gestational Age: Evaluation and Follow-up
- Author
-
Campos-Martorell, Ariadna, primary, Ramon, Alicia Montaner, additional, Barros, Karla Narváez, additional, Soria, José Luis Marin, additional, Galera, Rosa Maria López, additional, Fernández, Diego Yeste, additional, and León, María Clemente, additional
- Published
- 2022
- Full Text
- View/download PDF
19. Growth Hormone Treatment and Papilledema: A Prospective Pilot Study
- Author
-
Martín-Begué, Nieves, primary, Mogas, Eduard, additional, Dod, Charlotte Wolley, additional, Alarcón, Silvia, additional, Clemente, María, additional, Campos-Martorell, Ariadna, additional, Fábregas, Ana, additional, and Yeste, Diego, additional
- Published
- 2021
- Full Text
- View/download PDF
20. Growth Hormone Treatment and Papilledema : A Prospective Pilot Study
- Author
-
Martín-Begué, Nieves, Mogas, Eduard, Dod, Charlotte Wolley, Alarcón, Silvia, Clemente, María, Campos-Martorell, Ariadna, Fábregas, Ana, Yeste Fernández, Diego, Martín-Begué, Nieves, Mogas, Eduard, Dod, Charlotte Wolley, Alarcón, Silvia, Clemente, María, Campos-Martorell, Ariadna, Fábregas, Ana, and Yeste Fernández, Diego
- Abstract
To investigate the incidence of pseudotumor cerebri syndrome (PTCS) in children treated with growth hormone (GH) in a paediatric hospital and to identify risk factors for this complication. Prospective pilot study of paediatric patients treated with recombinant human GH, prescribed by the Paediatric Endocrinology Department, between February 2013 and September 2017. In all these patients, a fundus examination was performed before starting treatment and 3-4 months later. Two hundred and eighty-nine patients were included, of whom 244 (84.4%) had GH deficiency, 36 (12.5%) had short stature associated with small for gestational age, six (2.1%) had a mutation in the SHOX gene and three (1.0%) had Prader-Willi syndrome. Five (1.7%) developed papilledema, all were asymptomatic and had GH deficiency due to craniopharyngioma (n=1), polymalformative syndrome associated with hypothalamic-pituitary axis anomalies (n=2), a non-specified genetic disease with hippocampal inversion (n=1) and one with normal magnetic resonance imaging who had developed a primary PTCS years before. GH treatment is a cause of PTCS. In our series, at risk patients had GH deficiency and hypothalamic-pituitary anatomic anomalies or genetic or chromosomal diseases. Fundus examination should be systematically screened in all patients in this at-risk group, irrespective of the presence or not of symptoms.
- Published
- 2021
21. Función tiroidea en el recién nacido prematuro con edad gestacional igual o menor a 32 semanas
- Author
-
Montaner-Ramón, Alicia, primary, Hernández-Pérez, Susana, additional, Campos-Martorell, Ariadna, additional, Ballesta-Anguiano, Marta, additional, Clemente-León, María, additional, and Castillo- Salinas, Félix, additional
- Published
- 2020
- Full Text
- View/download PDF
22. Phenotypic Variability of Patients With PAX8 Variants Presenting With Congenital Hypothyroidism and Eutopic Thyroid
- Author
-
Camats, Núria, primary, Baz-Redón, Noelia, additional, Fernández-Cancio, Mónica, additional, Clemente, María, additional, Campos-Martorell, Ariadna, additional, Jaimes, Nadya, additional, Antolín, María, additional, Garcia-Arumí, Elena, additional, Blasco-Pérez, Laura, additional, Paramonov, Ida, additional, Mogas, Eduard, additional, Soler-Colomer, Laura, additional, and Yeste, Diego, additional
- Published
- 2020
- Full Text
- View/download PDF
23. 50 años del programa de cribado neonatal en Cataluña
- Author
-
Marín Soria, José Luis, López Galera, Rosa María, Argudo Ramírez, Ana, González de Aledo Castillo, Jose Manuel, Pajares García, Sonia, Navarro Sastre, Aleix, Hernandez Pérez, Jose Mª, Mogas Viñals, Eduardo, Giralt Arnaiz, Marina, Campistol Plana, Jaume, Blanco Álvarez, Adoración, Murillo Sanjuán, Laura, García Volpe, C., Parra Martínez, Alba, Asensio de la Cruz, Óscar, Yeste Fernández, Diego, Clemente León, María, García Cazorla, Ángels, Beneitez Pastor, David, Roué, Gaël, Velasco Puyó, Pablo, Mañú Pereira, María del Mar, Toro Riera, M. del, Ferrer, R., de los Santos Mercedes, M., Ruiz Hernández, Carlos José, Soler Palacín, Pere, Vidal Benede, Mª José, Fernández Bardon, Rosa Mª, Asso Ministral, Laia, Cabezas Peña, Carmen, Ribes Rubió, Antònia, Gort Mas, Laura, García Villoria, Judit, Gartner, Silvia, Rovira Amigo, Sandra, García González, Miguel, Cols Roig, María, Costa Colomer, Jordi, Badenas, Cèlia, Campos Martorell, Ariadna, Ortuño Cabrero, Ana, Tazón, Barbara, Murciano, Thais, Díaz de Heredia Rubio, C., Vives Corrons, Joan Lluís, Arranz, José Antonio, Carnicer Cáceres, Clara, Ormazabal Herrero, Aida, Artuch Iriberri, Rafael, Rivière, Jacques G., Martínez Gallo, Mònica, Prats, Blanca, Armelles Sebastia, Mercedes, Jané Checa, Mireia, Sierra March, Cristina, Meavilla Olivas, S., Martín Nalda, Andrea, Colobran Oriol, Roger, Casals Senent, Teresa, Marín Soria, José Luis, López Galera, Rosa María, Argudo Ramírez, Ana, González de Aledo Castillo, Jose Manuel, Pajares García, Sonia, Navarro Sastre, Aleix, Hernandez Pérez, Jose Mª, Mogas Viñals, Eduardo, Giralt Arnaiz, Marina, Campistol Plana, Jaume, Blanco Álvarez, Adoración, Murillo Sanjuán, Laura, García Volpe, C., Parra Martínez, Alba, Asensio de la Cruz, Óscar, Yeste Fernández, Diego, Clemente León, María, García Cazorla, Ángels, Beneitez Pastor, David, Roué, Gaël, Velasco Puyó, Pablo, Mañú Pereira, María del Mar, Toro Riera, M. del, Ferrer, R., de los Santos Mercedes, M., Ruiz Hernández, Carlos José, Soler Palacín, Pere, Vidal Benede, Mª José, Fernández Bardon, Rosa Mª, Asso Ministral, Laia, Cabezas Peña, Carmen, Ribes Rubió, Antònia, Gort Mas, Laura, García Villoria, Judit, Gartner, Silvia, Rovira Amigo, Sandra, García González, Miguel, Cols Roig, María, Costa Colomer, Jordi, Badenas, Cèlia, Campos Martorell, Ariadna, Ortuño Cabrero, Ana, Tazón, Barbara, Murciano, Thais, Díaz de Heredia Rubio, C., Vives Corrons, Joan Lluís, Arranz, José Antonio, Carnicer Cáceres, Clara, Ormazabal Herrero, Aida, Artuch Iriberri, Rafael, Rivière, Jacques G., Martínez Gallo, Mònica, Prats, Blanca, Armelles Sebastia, Mercedes, Jané Checa, Mireia, Sierra March, Cristina, Meavilla Olivas, S., Martín Nalda, Andrea, Colobran Oriol, Roger, and Casals Senent, Teresa
- Abstract
The Catalonian Newborn Screening Program (CNSP) began in 1969, in Barcelona. It was promoted by Dr. Juan Sabater Tobella and supported by Barcelona Provincial Council and Juan March Foundation. That is how the Institute of Clinical Biochemistry was born, whose aims were diagnosis, research and teaching, along with the spirit of contributing to the prevention of mental retardation. The CNSP began with the detection of phenylketonuria (PKU), and, in 1982, the Program was expanded with the inclusion of congenital hypothyroidism detection. Towards 1990, the Program covered almost 100% of all newborns (NB) in Catalonia. In 1999, the CNSP was expanded with the incorporation of cystic fibrosis. It took fourteen years, until 2013, to make the largest expansion so far, with the incorporation of 19 metabolic diseases to the screening panel. The detection of sickle cell disease began in 2015 and in 2017 the detection of severe combined immunodeficiency was included. Currently, the CNSP includes 24 diseases in its main panel. Since 1969, 2,787,807 NBs have been screened, of whom 1,724 have been diagnosed with any of these diseases, and 252 of other disorders by differential diagnosis with those included in the main panel. The global prevalence is 1: 1,617 NBs affected by any of the diseases included in the CNSP and 1: 1,140 NBs if incidental findings diagnosed through the CNSP are included., El Programa de Cribado Neonatal de Cataluña (PCNC) se inició en el año 1969, en Barcelona, impulsado por el Dr. Juan Sabater Tobella y apoyado por la Diputación de Barcelona y la Fundación Juan March. Así nació el Instituto de Bioquímica Clínica para acometer funciones asistenciales, de investigación y docencia, con el espíritu de contribuir a la prevención del retraso mental. El PCNC se inició con la detección de la fenilcetonuria (PKU) y en el año 1982 se amplió con la detección del hipotiroidismo congénito. Hacia el año 1990 la cobertura territorial llegó casi al 100% de todos los recién nacidos en Cataluña. En 1999 se amplió el PCNC con la incorporación de la fibrosis quística y tras catorce años, en 2013, se realizó la ampliación más numerosa hasta ahora, con la incorporación de la detección de 19 enfermedades metabólicas hereditarias. En el año 2015 comenzó la detección de la enfermedad de células falciformes y en el 2017 la detección de la inmunodeficiencia combinada grave. Actualmente, el PCNC incluye la detección de 24 enfermedades. Desde su inicio en el año 1969, se han cribado 2.787.807 recién nacidos, de los cuales 1.724 han sido diagnosticados de alguna de las 24 enfermedades que componen nuestro panel principal y 252 por diagnóstico diferencial de las primeras. En total la prevalencia global es de 1:1.617 RN afectos de alguna de las enfermedades incluidas en el PCNC y de 1:1.140 RN si se incluyen los hallazgos incidentales encontrados.
- Published
- 2020
24. Phenotypic Variability of Patients With PAX8 Variants Presenting With Congenital Hypothyroidism and Eutopic Thyroid.
- Author
-
Camats, Núria, Baz-Redón, Noelia, Fernández-Cancio, Mónica, Clemente, María, Campos-Martorell, Ariadna, Jaimes, Nadya, Antolín, María, Garcia-Arumí, Elena, Blasco-Pérez, Laura, Paramonov, Ida, Mogas, Eduard, Soler-Colomer, Laura, and Yeste, Diego
- Subjects
CONGENITAL hypothyroidism ,THYROID gland ,CHILD patients ,HORMONE synthesis ,THYROID hormones ,THYROID gland physiology ,NEWBORN screening ,THYROID gland function tests ,THERAPEUTICS ,RESEARCH ,HORMONES ,GENETIC mutation ,THYROXINE ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,PHENOTYPES ,LONGITUDINAL method - Abstract
Purpose: Thyroid dyshormonogenesis is a heterogeneous group of hereditary diseases produced by a total/partial blockage of the biochemical processes of thyroid-hormone synthesis and secretion. Paired box 8 (PAX8) is essential for thyroid morphogenesis and thyroid hormone synthesis. We aimed to identify PAX8 variants in patients with thyroid dyshormonogenesis and to analyze them with in vitro functional studies.Patients and Methods: Nine pediatric patients with a eutopic thyroid gland were analyzed by the Catalan screening program for congenital hypothyroidism. Scintigraphies showed absent, low, or normal uptake. Only one patient had a hypoplastic gland. On reevaluation, perchlorate discharge test was negative or compatible with partial iodine-organization deficit. After evaluation, 8 patients showed permanent mild or severe hypothyroidism. Massive-sequencing techniques were used to detect variants in congenital hypothyroidism-related genes. In vitro functional studies were based on transactivating activity of mutant PAX8 on a TG-gene promoter and analyzed by a dual-luciferase assays.Results: We identified 7 heterozygous PAX8 exonic variants and 1 homozygous PAX8 splicing variant in 9 patients with variable phenotypes of thyroid dyshormonogenesis. Five were novel and 5 variants showed a statistically significant impaired transcriptional activity of TG promoter: 51% to 78% vs the wild type.Conclusions: Nine patients presented with PAX8 candidate variants. All presented with a eutopic thyroid gland and 7 had deleterious variants. The phenotype of affected patients varies considerably, even within the same family; but, all except the homozygous patient presented with a normal eutopic thyroid gland and thyroid dyshormonogenesis. PAX8 functional studies have shown that 6 PAX8 variants are deleterious. Our studies have proven effective in evaluating these variants. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
25. Crecimiento en pacientes nacidos Pequeños para Edad Gestacional sin crecimiento recuperador tratados con hormona de crecimiento desde edad prepuberal hasta talla adulta
- Author
-
Campos Martorell, Ariadna, Yeste Fernández, Diego, Fernández Cancio, Mónica, and Universitat Autònoma de Barcelona. Departament de Pediatria, d'Obstetrícia i Ginecologia i de Medicina Preventiva
- Subjects
Pequeño para edad gestacional ,Petit per edat gestacional ,Hormona de creixement ,Growth ,Small for gestational age ,Crecimiento ,Creixement ,Hormona de crecimiento ,Growth hormone ,Ciències de la Salut - Abstract
Los nacidos Pequeños para Edad Gestacional (PEG) sin crecimiento recuperador son tributarios de recibir tratamiento con hormona de crecimiento (GH), que les permite alcanzar una talla adulta superior a menos de 2 desviaciones estándar (DE). Los objetivos del estudio son evaluar la evolución y la ganancia de talla, comparar el desarrollo puberal con la población de referencia [Estudios Españoles de Crecimiento 2010 (EEC 2010)], evaluar la variabilidad de la respuesta al tratamiento y las alteraciones en el perfil metabólico. Pacientes y métodos: Estudio descriptivo, longitudinal, observacional, retrospectivo y multicéntrico. Inicio de GH al menos 2 años antes del inicio de la pubertad. Dosis media 30 mcg/kg/día. Inicio de la pubertad definido por el incremento de la velocidad de crecimiento. Cohorte de 95 pacientes (64 varones y 31 mujeres), 21% prematuros. Peso y longitud medios al nacimiento de -1.9±0.8DE y -2.5±0.8DE, respectivamente. 78 pacientes alcanzaron talla adulta. Resultados: La edad de inicio del tratamiento fue de 6.98±2.15 años en niños y 5.94±1.74 años en niñas. Los niños recibieron tratamiento durante una media de 8.34 años y las niñas 7.81 años. La pubertad se inició a una edad media de 12.03 años en los niños y 10.17 años en las niñas. Edad media de la menarquía fue a los 13.04 años. La talla media al inicio del tratamiento fue -3.35DE, al inicio pubertad -1.78DE y a talla adulta -1.73DE. La ganancia de talla más importante fue durante el periodo prepuberal (+1.60DE). No hubo diferencias en la ganancia de talla adulta entre los pacientes clasificados según antecedente de prematuridad, según afectación de peso, longitud o ambos al nacimiento, según la respuesta a los test de estimulación de GH ni según el haber realizado discontinuación del tratamiento. Los pacientes PEG iniciaron la pubertad a la misma edad y tuvieron una distribución en los grupos maduradores igual que EEC 2010. Los PEG iniciaron la pubertad con una talla media inferior, y alcanzaron una talla adulta inferior respecto a EEC 2010. La ganancia puberal total de talla fue inferior en los PEG. Según la ganancia individual de talla desde el inicio del tratamiento hasta talla adulta, los pacientes se distribuyeron en cinco grupos: 1:0,5e≤1DE (13%), 3:>1e≤2DE (39%), 4:>2e≤3DE (26%),5:>3DE (9%). En los grupos 1, 2 y 3 se identifican tres patrones: A)mala respuesta desde el primer año de tratamiento, B)pérdida de talla durante pubertad, C)pérdida de talla desde finalización del tratamiento hasta talla adulta. La ganancia de talla adulta se correlacionó negativamente con el peso al inicio del tratamiento (R2=0.225) y positivamente con la velocidad de crecimiento durante el primer año de tratamiento (R2=0.225). Se observó un aumento progresivo de los valores de IGF-1 durante el tratamiento, para posteriormente mantenerse dentro de los límites normales y aumento de glucosa plasmática en ayunas en el periodo puberal y al finalizar tratamiento. No hubo alteraciones en el perfil lipídico. Conclusiones: Los PEG sin crecimiento recuperador tratados con GH alcanzaron una talla adulta superior a menos de 2DE. La mayor ganancia de talla fue durante la fase prepuberal. La edad de inicio de la pubertad y la distribución en los grupos maduradores fueron similares a la población de referencia. La respuesta al tratamiento con GH fue variable e individualizable. La ganancia de talla adulta se correlacionó negativamente con el peso al inicio del tratamiento y positivamente con la velocidad de crecimiento durante el primer año de tratamiento. Los tests de secreción de GH no predijeron mejor respuesta al tratamiento. El tratamiento con GH no comportó alteraciones en el perfil metabólico., Children born Small for Gestational Age (SGA) without catch-up growth can be treated with growth hormone (GH), which allows them to reach an adult height less than 2 standard deviations (SD). The aims of this study were to assess the long-term growth and the pubertal development compared to the reference population [Spanish Growth Studies 2010 (SGS 2010)], to evaluate the variability of the response to GH therapy, and to report changes in the metabolic profile. Patients and Methods: descriptive, longitudinal, observational, retrospective, multicenter study. GH was started at least 2 years before the onset of puberty. Mean daily GH dose was 30 mcg /kg/day. Onset of puberty was defined by an increase in growth velocity. There was a cohort of 95 patients (64 boys and 31 girls), 21% of them were preterm babies. Mean weight and length at birth were -1.9±0.8SD and -2.5±0.8SD, respectively. 78 patients reached adult-height. Results: Chronological age at the start of GH therapy was 6.98±2.1 years for boys and 5.94±1.74 for girls. Boys were treated for a mean of 8.34 years and girls for 7.81 years. Puberty onset was at mean age of 12.03 years for boys and 10.17 years for girls. Mean age of menarche was 13.04 years. Height-SD at start of GH therapy was -3.35SD, at pubertal growth spurt onset was -1.78SD and at adult-height was -1.73SD. The most important gain height was during the prepubertal period (+ 1.60SD). No differences at adult height gain were found among patients classified by being preterm, by being light, short or both at birth, by their response to GH stimulation test or by having had treatment discontinuation. Puberty onset of SGA patients and classification in their own growth standards were similar to the SGS 2010. SGA were shorter at puberty onset and also at adult-height compared to SGS 2010. Total pubertal height gain was lower in SGA. Depending on the individual height gain from the start of treatment until adult-height, patients were divided into five groups: 1: 0.5 andn≤1SD (13%), 3:>1 and ≤2SD (39%), 4:>2 and ≤3SD (26%), 5:>3SD (9%). Three growth patterns were identified in groups 1, 2 and 3: A) poor response from the beginning of the treatment, B) height loss during puberty, C) height loss from the end of treatment to adult-height. Adult height gain was negatively correlated with weight at baseline (R2= 0.225) and positively with growth velocity during the first year of treatment (R2= 0.225). There was a progressive increase of IGF-1 values during treatment that remained at the normal range afterwards. Increased fast plasmatic glucose levels were observed at puberty and at the end of treatment and no changes in lipid profile were reported. Conclusions: SGA without catch-up growth with GH therapy reached an adult height less than 2 SD. The greatest height gain was during the prepubertal period. Puberty onset of the SGA patients and classification in their own growth standards were similar to the reference population. Response to GH therapy is variable and should be individualized. Adult-height gain was negatively correlated with growth velocity during the first year of treatment. GH release after stimuli does not predict better response to GH therapy. No changes in the metabolic profile were reported.
- Published
- 2016
26. Phenotypic Variability of Patients With PAX8Variants Presenting With Congenital Hypothyroidism and Eutopic Thyroid
- Author
-
Camats, Núria, Baz-Redón, Noelia, Fernández-Cancio, Mónica, Clemente, María, Campos-Martorell, Ariadna, Jaimes, Nadya, Antolín, María, Garcia-Arumí, Elena, Blasco-Pérez, Laura, Paramonov, Ida, Mogas, Eduard, Soler-Colomer, Laura, and Yeste, Diego
- Published
- 2021
- Full Text
- View/download PDF
27. Crecimiento en pacientes nacidos Pequeños para Edad Gestacional sin crecimiento recuperador tratados con hormona de crecimiento desde edad prepuberal hasta talla adulta
- Author
-
Yeste Fernández, Diego, Fernández Cancio, Mónica, Campos Martorell, Ariadna, Universitat Autònoma de Barcelona. Departament de Pediatria, d'Obstetrícia i Ginecologia i de Medicina Preventiva, Yeste Fernández, Diego, Fernández Cancio, Mónica, Campos Martorell, Ariadna, and Universitat Autònoma de Barcelona. Departament de Pediatria, d'Obstetrícia i Ginecologia i de Medicina Preventiva
- Abstract
Los nacidos Pequeños para Edad Gestacional (PEG) sin crecimiento recuperador son tributarios de recibir tratamiento con hormona de crecimiento (GH), que les permite alcanzar una talla adulta superior a menos de 2 desviaciones estándar (DE). Los objetivos del estudio son evaluar la evolución y la ganancia de talla, comparar el desarrollo puberal con la población de referencia [Estudios Españoles de Crecimiento 2010 (EEC 2010)], evaluar la variabilidad de la respuesta al tratamiento y las alteraciones en el perfil metabólico. Pacientes y métodos: Estudio descriptivo, longitudinal, observacional, retrospectivo y multicéntrico. Inicio de GH al menos 2 años antes del inicio de la pubertad. Dosis media 30 mcg/kg/día. Inicio de la pubertad definido por el incremento de la velocidad de crecimiento. Cohorte de 95 pacientes (64 varones y 31 mujeres), 21% prematuros. Peso y longitud medios al nacimiento de -1.9±0.8DE y -2.5±0.8DE, respectivamente. 78 pacientes alcanzaron talla adulta. Resultados: La edad de inicio del tratamiento fue de 6.98±2.15 años en niños y 5.94±1.74 años en niñas. Los niños recibieron tratamiento durante una media de 8.34 años y las niñas 7.81 años. La pubertad se inició a una edad media de 12.03 años en los niños y 10.17 años en las niñas. Edad media de la menarquía fue a los 13.04 años. La talla media al inicio del tratamiento fue -3.35DE, al inicio pubertad -1.78DE y a talla adulta -1.73DE. La ganancia de talla más importante fue durante el periodo prepuberal (+1.60DE). No hubo diferencias en la ganancia de talla adulta entre los pacientes clasificados según antecedente de prematuridad, según afectación de peso, longitud o ambos al nacimiento, según la respuesta a los test de estimulación de GH ni según el haber realizado discontinuación del tratamiento. Los pacientes PEG iniciaron la pubertad a la misma edad y tuvieron una distribución en los grupos maduradores igual que EEC 2010. Los PEG iniciaron la pubertad con una talla media inferior, y alcanzar
- Published
- 2016
28. [Thyroid function in < 32 weeks gestation preterm infants].
- Author
-
Montaner-Ramón A, Hernández-Pérez S, Campos-Martorell A, Ballesta-Anguiano M, Clemente-León M, and Castillo-Salinas F
- Abstract
Introduction: Preterm newborns (PN) have a higher risk of thyroid dysfunction than term newborns (TN). This condition may go unnoticed in neonatal screening due to a late elevation of thyrotropin (TSH) in these patients., Objective: Evaluate thyroid function in the second week of life in PN of < 32 weeks gestation (WG), and to identify factors associated to its alteration., Patients and Methods: A retrospective study was performed in neonates of < 32 weeks gestation (WG), in whom thyroid function was determined. An analysis was performed on thyroxine (T4L) and TSH levels, as well as their association with perinatal and neonatal outcomes., Results: The study included a total of 358 patients with mean gestational age (GA) of 29.3 weeks, and mean birth weight (BW) 1127 grams. A linear correlation was found between T4L and BW (correlation coefficient (R) 0.356; p < 0.001) and GA (R = 0.442; p < 0.001). TSH values were associated with small for gestational age (SGA 5.3 mU/L [1.5-37]; non-SGA 2.89 mU/L [0.2-19.5]; p < 0.001), inotropic support (Yes 3.98 mU/L [0.6-22.9]; No 3.16 mU/L [0.2-37]; p = 0.019) and BW (R = -0.249; p < 0.001). Nine (2.5%) patients were treated with levothyroxine, of whom six were SGA., Conclusions: Thyroid function analysis in the second week of life helps to identify asymptomatic newborns with risk of thyroid dysfunction. SGA newborns are at higher risk of thyroid function alterations., (Copyright © 2020. Publicado por Elsevier España, S.L.U.)
- Published
- 2020
- Full Text
- View/download PDF
29. [50 years of the Neonatal Screening Program in Catalonia.]
- Author
-
Marín Soria JL, López Galera RM, Argudo Ramírez A, González de Aledo JM, Pajares García S, Navarro Sastre A, Hernandez Pérez JM, Ribes Rubio A, Gort Mas L, García Villoria J, Gartner Tizano S, Rovira Amigo S, Asensio de la Cruz O, García González M, Cols Roig M, Costa Colomer J, Bádenas Orquin C, Yeste Fernández D, Campos Martorell A, Clemente León M, Mogas Viñals E, Ferrer Costa R, Giralt Arnaiz M, Campistol Plana J, García Cazorla Á, Beneitez Pastor D, Ortuño Cabrero A, Blanco Álvarez A, Tazón Vega B, Roué G, Velasco Puyo P, Murciano Carrillo T, Murillo Sanjuan L, Díaz de Heredia Rubio C, Mañú Pereira MDM, Vives Corrons JL, Arranz Amo JA, Carnicer Cáceres C, Del Toro Riera M, Ormazábal Herrero A, Artuch Iriberri R, García-Volpe C, de Los Santos MM, Sierra March C, Ruiz Hernández CJ, Meavilla Olivas SM, Martín Nalda A, Rivière JG, Parra Martínez A, Soler Palacín P, Martínez Gallo M, Colobran R, Casals Senent T, Armelles Sebastia M, Vidal Benede MJ, Jané Checa M, Fernández Bordón RM, Asso Ministral L, Prats Viedma B, and Cabezas Peña C
- Subjects
- History, 20th Century, History, 21st Century, Humans, Infant, Newborn, Neonatal Screening methods, Neonatal Screening organization & administration, Spain, Neonatal Screening history
- Abstract
The Catalonian Newborn Screening Program (CNSP) began in 1969, in Barcelona. It was promoted by Dr. Juan Sabater Tobella and supported by Barcelona Provincial Council and Juan March Foundation. That is how the Institute of Clinical Biochemistry was born, whose aims were diagnosis, research and teaching, along with the spirit of contributing to the prevention of mental retardation. The CNSP began with the detection of phenylketonuria (PKU), and, in 1982, the Program was expanded with the inclusion of congenital hypothyroidism detection. Towards 1990, the Program covered almost 100% of all newborns (NB) in Catalonia. In 1999, the CNSP was expanded with the incorporation of cystic fibrosis. It took fourteen years, until 2013, to make the largest expansion so far, with the incorporation of 19 metabolic diseases to the screening panel. The detection of sickle cell disease began in 2015 and in 2017 the detection of severe combined immunodeficiency was included. Currently, the CNSP includes 24 diseases in its main panel. Since 1969, 2,787,807 NBs have been screened, of whom 1,724 have been diagnosed with any of these diseases, and 252 of other disorders by differential diagnosis with those included in the main panel. The global prevalence is 1: 1,617 NBs affected by any of the diseases included in the CNSP and 1: 1,140 NBs if incidental findings diagnosed through the CNSP are included.
- Published
- 2020
30. Hypophosphatasia: A Novel Mutation Associated with an Atypical Newborn Presentation
- Author
-
Esmel-Vilomara R, Hernández S, Campos-Martorell A, González-Roca E, Yeste D, and Castillo F
- Subjects
- Humans, Infant, Newborn, Infant, Premature, Male, Mutation, Phenotype, Alkaline Phosphatase genetics, Hypophosphatasia diagnosis, Hypophosphatasia genetics
- Abstract
Hypophosphatasia, a rare genetic disease affecting bone metabolism, is characterized by decreased activity of tissue non-specific alkaline phosphatase (TNAP). The gene encoding TNAP (ALPL) has considerable allelic heterogeneity, which could explain different degrees of enzyme activity resulting in a wide clinical variability. We report the case of a preterm newborn in whom a corneal opacity was detected at birth. Blood tests performed to investigate this finding showed low alkaline phosphatase concentrations. The corneal opacity disappeared within a week but alkaline phosphatase remained persistently low. With persistently decreased levels of alkaline phosphatase, upon suspicion of hypophosphatasia, plain radiography detected changes suggestive of rickets. Sequencing of the ALPL gene revealed a heterozygous variant that has not been described in the literature to date. Our patient’s condition may be an atypical neonatal form of the syndrome, with a mild phenotype, very different from the classic neonatal form, which can lead to severe skeletal disease and respiratory failure. However, it could also be an early diagnosis of the childhood form, which is associated with a better prognosis.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.